Clinical trials: Acarbose
Type 2 Diabetes Mellitus
A Phase IV Study in Drug-Naive Patients With T2DM in China
This is a 24-week, multicenter, randomized, open-label, parallel-group, active controlled Phase IV study to assess the efficacy and safety of Dapagliflozin as monotherapy compared with Acarbose in patients with T2DM who were…
- Trial name
- NCT03344341
- Testing
- Dapagliflozin, Acarbose
- Where
- 20 sites in China
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care
The purpose of the study is to determine if the administration of small doses of Acarbose can prevent or delay the appearance of Type 2 Diabetes Mellitus in a population of subjects with prediabetes.
- Trial name
- NCT01010100
- Testing
- Acarbose (Glucobay, BAYG5421)
- Where
- 23 sites in Spain
- Volunteers
- 204 people
- Sponsor
- Bayer
Tolerance, Side Effect
The Efficacy and Tolerability of Acarbose in Healthy Individuals
A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.
- Conditions
- Tolerance, Side Effect, Glucose Response
- Trial name
- NCT05542849
- Testing
- Acarbose Tablets 50mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AgelessRx
Type 2 Diabetes Mellitus
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared with Acarbose when in Combination with…
- Trial name
- SMART (NCT02243176)
- Testing
- Saxagliptin, Acarbose
- Where
- China
- Volunteers
- 689 people
- Sponsor
- AstraZeneca
Overweight or Obesity
Study Exploring the Supportive Effect of Acarbose in Weight Management
This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination…
- Trial name
- NCT05934110
- Testing
- EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg,
- Where
- 3 sites in Sweden
- Volunteers
- 320 people
- Sponsor
- Empros Pharma AB
Type 2 Diabetes
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes
This study is aimed to investigate the effect of acarbose on intestinal microbiome and incretins, therefore to explore the new pathways or new targets to treat type 2 diabetes.
- Trial name
- NCT01758471
- Testing
- Glipizide, Acarbose
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes
This study is not being conducted in the United States. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to acarbose in lowering overall blood glucose levels in…
- Trial name
- NCT00110240
- Testing
- vildagliptin
- Where
- Switzerland
- Volunteers
- 594 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Cancer
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
The purpose of this study is to determine the safety and tolerability of acarbose in combination of immunotherapy based standard of care therapy in advanced renal cell carcinoma patients.
- Trial name
- NCT05487859
- Testing
- Acarbose Tablets
- Sponsor
- University of Alabama at Birmingham
Diabetes Mellitus, Type II
Bioequivalence Study for Acarbose / Metformin FDC
To establish the bioequivalence between Acarbose / Metformin FDC (50mg / 500mg) and loose combination of Acarbose (Glucobay) (50mg) and Metformin (Glucophage) (500mg).
- Trial name
- NCT01728740
- Testing
- Acarbose/Metformin FDC (BAY81-9783), Acarbose (Glucobay, BAYG5421), Metformin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
Primary objective To evaluate the efficacy of Acarbose add-on therapy on glucose control in subjects with type 2 diabetes inadequately controlled with Metformin and Sitagliptin combination therapy.
- Trial name
- NCT01490918
- Testing
- Acarbose
- Where
- South Korea
- Volunteers
- 165 people
- Sponsor
- The Catholic University of Korea
Aging
Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)
This study addresses a "lifespan approach to healthy development and aging" with direct relevance to humans by testing the anti-aging effects of acarbose in humans.
- Trial name
- NCT02865499
- Testing
- acarbose
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus, Subclinical Inflammation
AI(I)DA Acarbose and the Subclinical Inflammation
Acarbose an alphaglucosidase inhibitor changes in a complex way the transport, the digestion and the place of glucose release and absorption.
- Trial name
- NCT00558883
- Testing
- acarbose
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- GWT-TUD GmbH
Type 2 Diabetes
Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose
The aim of the study is to compare the FGM glycemic profiles in patients with type 2 diabetes mellitus treated with sitagliptin and acarbose.
- Trial name
- NCT05035849
- Testing
- sitagliptin and acarbose
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Glucose Intolerance, Postprandial Hyperglycemia
Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients
Is a randomized, double-blind, placebo-controlled trial to determine the behavior of hyperglycemia and postprandial lipemia after a standard mixed meal load in patients with carbohydrate intolerance treated with acarbose.
- Conditions
- Glucose Intolerance, Postprandial Hyperglycemia, Cardiovascular Risk Factor
- Trial name
- NCT02355509
- Testing
- Acarbose
- Where
- Mexico
- Volunteers
- 21 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in
A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is a chronic metabolic disorder which is caused by both insulin secretion deficiency and insulin action defect.
- Conditions
- The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in, Subjects With Type 2 Diabetes Mellitus.
- Trial name
- NCT01245166
- Testing
- Acarbose, Metformin/Acarbose
- Where
- Taiwan
- Volunteers
- 220 people
- Sponsor
- Lotus Pharmaceutical
Type 2 Diabetes Mellitus
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
To assess the effect of adding acarbose or repaglinide or gliclazide to sitagliptin plus metformin, compared to adding glimepiride, on glycemic improvements in Type 2 Diabetes Mellitus (T2DM) participants who require the addition…
- Trial name
- NCT01709305
- Testing
- Metformin, Sitagliptin, Acarbose
- Volunteers
- 5,570 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease
The use of acarbose in impaired glucose tolerance (IGT) and type 2 diabetic subjects has been associated with a significant reduction of cardiovascular events.
- Trial name
- ABDOMEN (NCT01167231)
- Testing
- Acarbose (Glucobay, BAYG5421)
- Where
- Poland
- Volunteers
- 3,310 people
- Sponsor
- Bayer
Type 2 Diabetes
Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes
The proposed study is designed to evaluate (i) the effects of saxagliptin, with or without acarbose, on gastric emptying, postprandial glycaemia, and plasma intact GLP-1, insulin, C-peptide and glucagon after a high carbohydrate…
- Trial name
- NCT02315495
- Testing
- Saxagliptin, Acarbose
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Zilin Sun
Diabetes Mellitus, Type 2
GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice
The study is designed as non interventional to collect data on the safety especially, severe hypoglycemia or documented symptomatic hypoglycemic episodes and effectiveness of acarbose/metformin fixed-dose combination under…
- Trial name
- GLORY (NCT01915264)
- Testing
- Acarbose/Metformin (Glucobay M, BAY81-9783)
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
To demonstrate the efficacy and safety of acarbose and metformin loose-dose combination as compared to metformin monotherapy in the treatment of subjects with T2DM that is inadequately controlled by metformin alone
- Trial name
- NCT03349684
- Testing
- Acarbose, Metformin
- Where
- 29 sites in China
- Volunteers
- 287 people
- Sponsor
- Bayer